novartis pharma schweiz ag 中国首次上市年份 / 首次上市国家 欧盟 首次上市年份 2007-01-15 治疗疾病 原发性高血压 靶点 作用机制 angiotensin ii receptor type 1 antagonists (血管紧张素ii-1型受体拮抗剂);voltage-gated calcium channel blockers (电压门控性钙通道复合体阻滞剂) atc c09db01➜c 心血管...
缬沙坦片主要用于治疗轻、中度原发性高血压。 该药品由诺华制药研发,于2001年7月在美国批准上市。当前,缬沙坦片的美国主要生产厂商有solco healthcare, and camber pharma等,国内主要生产厂商有北京诺华制药有限公司、 常州四药制药有限公司、浙江华海药业股份有限公司。 2017 年,缬沙坦片美国市场销售额约6100万美元...
2019. https://www.pharma.us.novartis.com/news/media-releases/novartis-entresto-receives-fda-approval-pediatric-heart-failure-helping-address. Accessed 22 July 2020. Shaddy R, Canter C, Halnon N, Kochilas L, Rossano J, Bonnet D, et al. Design for the sacubitril/valsartan (LCZ696) compared...
Ramipril1, (1S,5S, 7S)-8-[(2S)-2-[[(1S)-1-ethoxycarbonyl- 3-phenyl-propyl] amino] propanoyl] -8- azabicyclo 3.3.0] octane-7-carboxylic acid is an Angiotensin convertase inhibitor used in the treatment of Hypertension. Literature survey reveals that several spectrophotometric and spectro...
Heart failure (HF) represents a significant global health challenge, characterized by high morbidity and mortality rates, decreased quality of life and a s
Kimura M, Mitani H, Isomura Y, Division R, Institute TR, Pharma NKK (2002). Preclinical and clinical profile of Valsartan, a selective angiotensin II type-1 receptor blocker. Nippon Yakurigaku Zasshi 120:353-360.Kimura M,Mitani H,Isomura Y.Preclinical and clinical profile of Valsartan,a ...
Die Pharmazie- An International Journal of Pharmaceutical Sciences, 63, 337-341.Habib, I. H. I.; Weshahy, S. A.; Toubar, S. S.; El-Alamin, M. M. A. Stripping Voltammetric Determi- nation of Valsartan in Bulk and Pharmaceutical Products. Pharmazie 2008, 63, 337-341....
A.El-BagaryR.PatonayG.Ebeid W. et al.: Simultaneous determination of valsartan, amlodipine besylate and hydrochlorothiazide using capillary zone electrophoresis (CZE). Pharmazie, 70, 368, 2015.Ebeid W, Salim M,Elkady E,et al.Simultaneous determi- nation of valsartan, amlodipine besylate and ...
The conditions optimized were: flow rate (1 ml/minute), wavelength (210 nm) and run time was 20 min. Retention time was found to be 6.22 min. The linearity was found to be in the concentration range of 10-100 g/ml. The developed method was evaluated in the assay of commercially ...
美国上市药品目录集提供Valsartan的基本信息,包括Valsartan的申请号214102,申请类型,活性成分Valsartan,中文名称缬沙坦,申请机构,批准日期等药品信息,更多美国药品Valsartan的信息查询就在戊戌数据美国上市药品数据库.